{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:13:30Z","timestamp":1768454010334,"version":"3.49.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cbpc.2024.109962","type":"journal-article","created":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T21:57:09Z","timestamp":1718575029000},"page":"109962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Glucuronidation of tizoxanide, an active metabolite of nitazoxanide, in liver and small intestine: Species differences in humans, monkeys, dogs, rats, and mice and responsible UDP-glucuronosyltransferase isoforms in humans"],"prefix":"10.1016","volume":"283","author":[{"given":"Nobumitsu","family":"Hanioka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Jinno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Ohkawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiko","family":"Tanaka-Kagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cbpc.2024.109962_bb0005","doi-asserted-by":"crossref","first-page":"11169","DOI":"10.1007\/s11033-022-07822-2","article-title":"Nitazoxanide and COVID-19: a review","volume":"49","author":"Al-Kuraishy","year":"2022","journal-title":"Mol. Biol. Rep."},{"issue":"9343","key":"10.1016\/j.cbpc.2024.109962_bb0010","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(02)11401-2","article-title":"Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial","volume":"360","author":"Amadi","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cbpc.2024.109962_bb0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1358\/dot.2021.57.7.3235211","article-title":"Role of nitazoxanide as a repurposed drug in the treatment and management of various diseases","volume":"57","author":"Bharti","year":"2021","journal-title":"Drugs Today (Barc.)"},{"issue":"2","key":"10.1016\/j.cbpc.2024.109962_bb0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11908-006-0003-y","article-title":"Use of nitazoxanide for gastrointestinal tract infections: treatment of protozoan parasitic infection and beyond","volume":"8","author":"Bobak","year":"2006","journal-title":"Curr. Infect. Dis. Rep."},{"issue":"8","key":"10.1016\/j.cbpc.2024.109962_bb0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5414\/CPP38387","article-title":"Nitazoxanide: pharmacokinetics and metabolism in man","volume":"38","author":"Broekhuysen","year":"2000","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"20","key":"10.1016\/j.cbpc.2024.109962_bb0030","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/0024-3205(95)02073-R","article-title":"Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation","volume":"57","author":"Burchell","year":"1995","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.cbpc.2024.109962_bb0035","first-page":"1165","article-title":"Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10","volume":"27","author":"Cheng","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"19","key":"10.1016\/j.cbpc.2024.109962_bb0040","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1021\/jm9010719","article-title":"Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance","volume":"52","author":"de Carvalho","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbpc.2024.109962_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104148","article-title":"Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2","volume":"82","author":"Driouich","year":"2022","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.cbpc.2024.109962_bb0050","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1128\/AAC.40.10.2266","article-title":"In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms","volume":"40","author":"Dubreuil","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.cbpc.2024.109962_bb0055","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1124\/dmd.113.053801","article-title":"Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography\/tandem mass spectrometry with selected reaction monitoring","volume":"41","author":"Fallon","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbpc.2024.109962_bb0060","article-title":"A randomized, open-label trial of combined nitazoxanide and atazanavir\/ritonavir for mild to moderate COVID-19","volume":"9","author":"Fowotade","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"issue":"8","key":"10.1016\/j.cbpc.2024.109962_bb0065","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1086\/428839","article-title":"Nitazoxanide: a new thiazolide antiparasitic agent","volume":"40","author":"Fox","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.cbpc.2024.109962_bb0070","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/jac\/dkr077","article-title":"Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole","volume":"66","author":"Freeman","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.cbpc.2024.109962_bb0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/aid.2014.0015","article-title":"Short communication: nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages","volume":"31","author":"Gekonge","year":"2015","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"3","key":"10.1016\/j.cbpc.2024.109962_bb0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1471-4922(01)02205-X","article-title":"Treatment of intestinal parasitic infections: a review of nitazoxanide","volume":"18","author":"Gilles","year":"2002","journal-title":"Trends Parasitol."},{"issue":"6","key":"10.1016\/j.cbpc.2024.109962_bb0085","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/chromsci\/bms041","article-title":"Validated and optimized high-performance liquid chromatographic determination of tizoxanide, the main active metabolite of nitazoxanide in human urine, plasma and breast milk","volume":"50","author":"Hadad","year":"2012","journal-title":"J. Chromatogr. Sci."},{"issue":"10","key":"10.1016\/j.cbpc.2024.109962_bb0090","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/00498250110057341","article-title":"Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin","volume":"31","author":"Hanioka","year":"2001","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.cbpc.2024.109962_bb0095","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/ac201704a","article-title":"Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry","volume":"84","author":"Harbourt","year":"2012","journal-title":"Anal. Chem."},{"issue":"8","key":"10.1016\/j.cbpc.2024.109962_bb0100","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.cbpc.2024.109962_bb0105","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/AAC.01159-06","article-title":"Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni","volume":"51","author":"Hoffman","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbpc.2024.109962_bb0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jchromb.2015.05.025","article-title":"Metabolism of nitazoxanide in rats, pigs, and chickens: application of liquid chromatography coupled to hybrid linear ion trap\/Orbitrap mass spectrometer","volume":"1000","author":"Huang","year":"2015","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"12","key":"10.1016\/j.cbpc.2024.109962_bb0115","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1345\/aph.1H340","article-title":"Emerging therapies in the treatment of Clostridium difficile-associated disease","volume":"40","author":"Jodlowski","year":"2006","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.cbpc.2024.109962_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","article-title":"UDP-glucuronosyltransferases and clinical drug-drug interactions","volume":"106","author":"Kiang","year":"2005","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.cbpc.2024.109962_bb0125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/1389200003339171","article-title":"UDP-glucuronosyltransferases","volume":"1","author":"King","year":"2000","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.cbpc.2024.109962_bb0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2007.08.005","article-title":"Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication","volume":"77","author":"Korba","year":"2008","journal-title":"Antiviral Res."},{"issue":"20","key":"10.1016\/j.cbpc.2024.109962_bb0135","doi-asserted-by":"crossref","first-page":"11096","DOI":"10.1128\/JVI.01213-13","article-title":"Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation","volume":"87","author":"La Frazia","year":"2013","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.cbpc.2024.109962_bb0140","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1210\/jc.2004-0331","article-title":"Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium","volume":"89","author":"L\u00e9pine","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.cbpc.2024.109962_bb0145","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/bmc.3748","article-title":"Simultaneous quantification of tizoxanide and tizoxanide glucuronide in mouse plasma by liquid chromatography-tandem mass spectrometry","volume":"30","author":"Liu","year":"2016","journal-title":"Biomed. Chromatogr."},{"issue":"10","key":"10.1016\/j.cbpc.2024.109962_bb0150","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"issue":"9","key":"10.1016\/j.cbpc.2024.109962_bb0155","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1128\/AAC.44.9.2254-2258.2000","article-title":"In vitro and in vivo activities of nitazoxanide against Clostridium difficile","volume":"44","author":"McVay","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.cbpc.2024.109962_bb0160","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1128\/AAC.42.11.2836","article-title":"Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole","volume":"42","author":"M\u00e9graud","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.cbpc.2024.109962_bb0165","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0163-7258(91)90065-T","article-title":"Drug glucuronidation in humans","volume":"51","author":"Miners","year":"1991","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cbpc.2024.109962_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108459","article-title":"Drug-drug interactions that alter the exposure of glucuronidated drugs: scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance","volume":"248","author":"Miners","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cbpc.2024.109962_bb0175","series-title":"Conjugation Reactions in Drug Metabolism","first-page":"51","article-title":"Glucuronidation","author":"Mulder","year":"1990"},{"issue":"4","key":"10.1016\/j.cbpc.2024.109962_bb0180","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1086\/506351","article-title":"Nitazoxanide for the treatment of Clostridium difficile colitis","volume":"43","author":"Musher","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.cbpc.2024.109962_bb0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1086\/596552","article-title":"Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study","volume":"48","author":"Musher","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.cbpc.2024.109962_bb0190","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.dmpk.2014.12.001","article-title":"A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development","volume":"30","author":"Oda","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.cbpc.2024.109962_bb0195","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/dmd.111.042259","article-title":"Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities","volume":"40","author":"Ohtsuki","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.cbpc.2024.109962_bb0200","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1046\/j.1365-2036.2001.01066.x","article-title":"Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru","volume":"15","author":"Ortiz","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cbpc.2024.109962_bb0205","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1128\/AAC.50.3.1112-1117.2006","article-title":"Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species","volume":"50","author":"Pankuch","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.cbpc.2024.109962_bb0210","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1111\/bcp.14619","article-title":"Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis","volume":"87","author":"Rajoli","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.cbpc.2024.109962_bb0215","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0009-2797(00)00198-8","article-title":"Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions","volume":"129","author":"Ritter","year":"2000","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.cbpc.2024.109962_bb0220","article-title":"Bibliometric assessment of the global scientific production of nitazoxanide","volume":"9","author":"Rodriguez-Morales","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.cbpc.2024.109962_bb0225","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.cbpc.2024.109962_bb0230","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4269\/ajtmh.1984.33.511","article-title":"Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections","volume":"33","author":"Rossignol","year":"1984","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"1","key":"10.1016\/j.cbpc.2024.109962_bb0235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1086\/321008","article-title":"Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide","volume":"184","author":"Rossignol","year":"2001","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.cbpc.2024.109962_bb0240","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"5","key":"10.1016\/j.cbpc.2024.109962_bb0245","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1124\/dmd.113.056291","article-title":"Optimized methods for targeted peptide-based quantification of human uridine 5\u2032-diphosphate-glucuronosyltransferases in biological specimens using liquid chromatography-tandem mass spectrometry","volume":"42","author":"Sato","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.cbpc.2024.109962_bb0250","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/bj3030233","article-title":"Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation","volume":"303","author":"Senafi","year":"1994","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.cbpc.2024.109962_bb0255","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/1570163814666170727130003","article-title":"Update on nitazoxanide: a multifunctional chemotherapeutic agent","volume":"15","author":"Shakya","year":"2018","journal-title":"Curr. Drug Discov. Technol."},{"issue":"1","key":"10.1016\/j.cbpc.2024.109962_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molbiopara.2013.12.002","article-title":"Nitazoxanide: nematicidal mode of action and drug combination studies","volume":"193","author":"Somvanshi","year":"2014","journal-title":"Mol. Biochem. Parasitol."},{"issue":"6","key":"10.1016\/j.cbpc.2024.109962_bb0265","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1021\/acsinfecdis.0c00478","article-title":"Therapeutic potential of nitazoxanide: an appropriate choice for repurposing versus SARS-CoV-2?","volume":"7","author":"Stachulski","year":"2021","journal-title":"ACS Infect. Dis."},{"issue":"5","key":"10.1016\/j.cbpc.2024.109962_bb0270","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ijpara.2004.01.006","article-title":"Secondary and primary murine alveolar echinococcosis: combined albendazole\/nitazoxanide chemotherapy exhibits profound anti-parasitic activity","volume":"34","author":"Stettler","year":"2004","journal-title":"Int. J. Parasitol."},{"issue":"5","key":"10.1016\/j.cbpc.2024.109962_bb0275","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5414\/CPP40213","article-title":"Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses","volume":"40","author":"Stockis","year":"2002","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.cbpc.2024.109962_bb0280","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5414\/CPP40221","article-title":"Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d","volume":"40","author":"Stockis","year":"2002","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbpc.2024.109962_bb0285","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.antiviral.2017.10.002","article-title":"The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide","volume":"147","author":"Tilmanis","year":"2017","journal-title":"Antiviral Res."},{"issue":"12","key":"10.1016\/j.cbpc.2024.109962_bb0290","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1124\/dmd.30.12.1462","article-title":"Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10","volume":"30","author":"Watanabe","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.cbpc.2024.109962_bb0295","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jchromb.2008.09.017","article-title":"Liquid chromatography-tandem mass spectrometry analysis of nitazoxanide and its major metabolites in goat","volume":"875","author":"Zhao","year":"2008","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"9\u201310","key":"10.1016\/j.cbpc.2024.109962_bb0300","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1365\/s10337-008-0769-1","article-title":"Metabolic profile of nitazoxanide in goat feces","volume":"68","author":"Zhao","year":"2008","journal-title":"Chromatographia"},{"issue":"2","key":"10.1016\/j.cbpc.2024.109962_bb0305","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2885.2009.01119.x","article-title":"The pharmacokinetics of nitazoxanide active metabolite (tizoxanide) in goats and its protein binding ability in vitro","volume":"33","author":"Zhao","year":"2010","journal-title":"J. Vet. Pharmacol. Ther."}],"container-title":["Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1532045624001303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1532045624001303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T00:38:06Z","timestamp":1722127086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1532045624001303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":61,"alternative-id":["S1532045624001303"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpc.2024.109962","relation":{},"ISSN":["1532-0456"],"issn-type":[{"value":"1532-0456","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucuronidation of tizoxanide, an active metabolite of nitazoxanide, in liver and small intestine: Species differences in humans, monkeys, dogs, rats, and mice and responsible UDP-glucuronosyltransferase isoforms in humans","name":"articletitle","label":"Article Title"},{"value":"Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpc.2024.109962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109962"}}